May 5, 2021
Dani joined AXA IM in April 2015 from Barclays Capital where he had worked as a senior equity research analyst covering European healthcare. Prior to this he covered global healthcare at Nomura as a sector specialist and spent nine years as senior pharmaceutical analyst at Goldman Sachs, specialising in European Pharmaceuticals. Dani graduated from Leeds University with a BSc (First Class Honours) in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
It is anticipated that Pacific Asset Management (PAM) will launch a new fund for Dani to manage in due course.
Matthew Lamb, CEO, Pacific Asset Management, said: “We have long recognised Dani’s talent and we are thrilled that he has decided to join our team. We have built from scratch a technologically advanced fund management business with a supportive framework which allows our fund managers to follow their conviction and invest where they see the greatest opportunity.”
“The longevity economy, demographic shifts and social change driven by a gravitation to a more sustainable world, are critical areas for investors in the next decade. We want to deliver forward-looking strategies for our clients to benefit while supporting these trends. We look forward to welcoming Dani and building his team to support an exciting new global equity proposition at Pacific Asset Management.”
Dani Saurymper commented: “I am excited to be joining the team at PAM who share my passion for investing in secular growth themes such as demographics and healthcare. Longevity is altering societies globally and is arguably this century’s greatest social, economic and political transformation. It will have significant implications for how we live and work and what we do once we retire.”
“A vast array of industries are set to benefit from an ageing society and by leveraging a responsible investment philosophy, identifying companies with strong ESG credentials that are positioned to benefit from secular tailwinds, we will aim to deliver a unique and differentiated equity value proposition for investors.”